

Dominion Nuclear Connecticut, Inc.  
Millstone Power Station  
Rope Ferry Road  
Waterford, CT 06385



MAY - 2 2001

Docket Nos. 50-245  
50-336  
50-423  
B18402

RE: 10 CFR 26, Appendix A

U.S. Nuclear Regulatory Commission  
Attention: Document Control Desk  
Washington, DC 20555

Millstone Nuclear Power Station, Unit Nos. 1, 2 and 3  
10 CFR 26, Appendix A, Subpart B, Section 2.8(e)(4) Report  
Unsatisfactory Laboratory Performance Testing Incident

Pursuant to 10 CFR 26, Appendix A, "Guidelines For Drug And Alcohol Testing Programs," Subpart B, "Scientific And Technical Requirements," Section 2.8, "Quality Assurance and Quality Control," Item (e)(4), "Licensee Blind Performance Test Procedures," Dominion Nuclear Connecticut, Inc. (DNC) submits the investigative findings and corrective action taken by our testing laboratory, Quest Diagnostic Incorporated (see Enclosure 1), from their investigation of an unsatisfactory performance test result 'false negative.' This performance test result is from a Department of Health and Human Services (DHHS) certified laboratory under contract to DNC to perform drug testing as required by 10 CFR Part 26 in support of the Dominion Nuclear Connecticut, Inc. Fitness For Duty (FFD) Program.

On April 7, 2001, Quest Diagnostic Incorporated processed blind specimen #9848179 (T0101109615), and following the confirmatory test reported the specimen as negative on April 9, 2001. Subsequently, on April 10, 2001, the specimen was determined to be positive upon retesting. Enclosure 1 provides Quest Diagnostic's Incorporated report of its investigation of this incident, dated April 12, 2001, as required by 10 CFR 26, Appendix A, Subpart B, Section 2.8(e)(4). As stated in this report, the individual involved in this incident has been re-trained.


There are no regulatory commitments contained within this letter.

4022/1

If you have any questions regarding this submittal, please contact Mr. Paul Willoughby at (860) 447-1791, extension 3655.

Very truly yours,

DOMINION NUCLEAR CONNECTICUT, INC.



---

Raymond P. Necci

Vice President - Nuclear Technical Services

Enclosure 1) Re: Specimen #9848179 (T0101109615), Investigation Report on Blind Performance Test Sample Prepared by Quest Diagnostics Incorporated, dated April 12, 2001

cc: H. J. Miller, Region I Administrator  
J. B. Hickman, NRC Project Manager, Millstone Unit No. 1  
P. C. Cataldo, Resident Inspector, Millstone Unit No. 2  
D. S. Collins, NRC Project Manager, Millstone Unit No. 2  
S. R. Jones, Senior Resident Inspector, Millstone Unit No. 2  
V. Nerses, NRC Senior Project Manager, Millstone Unit No. 3  
A. C. Cerne, Senior Resident Inspector, Millstone Unit No. 3

Docket Nos. 50-245

50-336

50-423

B18402

Enclosure 1

Millstone Nuclear Power Station, Unit Nos. 1, 2 and 3

Re: Specimen #9848179 (T0101109615)

Investigation Report on Blind Performance Test Sample Prepared by  
Quest Diagnostics Incorporated, dated April 12, 2001

**Quest Diagnostics Incorporated**

One Malcolm Avenue  
Teterboro, New Jersey 07608-1070  
201.393.5000  
212.736.0640



April 12, 2001

Jay A. Graves, MD/MRO  
P.O. Box 128  
Bldg. 532/1 Fitness for Duty  
Waterford, CT 06385

**Re: Specimen # 9848179 (T0101109615)**

Dear Dr. Graves:

In response to the request received from Ms. Cora Quinn-Ross on April 10, 2001 regarding the NU blind specimen T0101109615, the laboratory conducted a full investigation and determined the following.

Specimen T0101109615 was received by Quest Diagnostics Inc. on 4/7/01. The specimen was screened positive for amphetamines by the Enzyme Multiplied Immunoassay Technique (EMIT) test on 4/7/01.

The confirmatory test for amphetamines by Gas Chromatography/Mass Spectrometry (GC/MS ) produced a negative result for both amphetamine and methamphetamine. Accordingly, the specimen was certified and reported to you as negative on 4/9/01.

A retest of the specimen by GC/MS on 4/10/01, confirmed the presence of amphetamine in the specimen at a concentration of 740 ng/mL. The Custody and Control Form and the Laboratory Report have been corrected and faxed to you on 4/11/01.

A complete review of the original GC/MS chromatographic data and chain of custody records showed that this error most likely occurred during the extraction of the specimen for GC/MS analysis. The laboratory procedure requires the extractionist to handle one specimen at a time and to verify the specimen number during each and every extraction step. It appears that the extractionist inadvertently made a mistake during one of the extraction steps.

As part of the corrective action, the individual responsible for the error has been disciplined and re-trained in the proper procedure for extraction. As indicated above, the laboratory has in place procedures to prevent this types of errors. Unfortunately, the individual responsible for the error did not follow these procedures.

We regret any inconvenience this may have caused. If you have any questions, concerns or need additional information, please contact me at ( 800-222-0446, Ext. 4284 ).

Sincerely,

A handwritten signature in black ink, appearing to read "H. Othman".

Hashim Othman, Ph.D.  
Alternate Responsible Person